Pharmacokinetic Evaluation of BP1.4979 in Sustained vs. Immediate Release Formulations in Binge Eating Disorder: A Two-Part Study in Healthy Subjects

The primary objective of this study is to evaluate the **pharmacokinetics** of BP1.4979 in healthy subjects. This is achieved through a two-part investigation: Part I focuses on the relative bioavailability of BP1.4979 by comparing its pharmacokinetics after administration of single oral doses in both sustained release and immediate release formulations, under fasting and fed conditions. Part II examines the pharmacokinetics of BP1.4979 following a 14-day dosing period with twice-daily administration of the sustained release formulation. Understanding the pharmacokinetics of BP1.4979 is clinically relevant as it may inform dosing strategies and optimize therapeutic outcomes for conditions such as **binge eating disorder**.

The clinical trial involves participants diagnosed with **binge eating disorder**. The study population includes both male and female subjects, with an age range of 18 to 65 years. Participants are generally in good health, aside from their primary condition. The sponsor has not provided information regarding the total number of participants. The trial population was selected without targeting any vulnerable groups. Lifestyle considerations such as diet, physical activity, and habits were not specified by the sponsor. Key inclusion or exclusion criteria were not disclosed.

The clinical trial is designed as an **open-label**, single-center, two-part pharmacokinetic study. The trial aims to evaluate the pharmacokinetics of BP1.4979 in healthy subjects. Part I of the study will assess the relative bioavailability of BP1.4979 by comparing the pharmacokinetics of single oral doses of BP1.4979 in sustained release and immediate release formulations under both fasting and fed conditions. Part II will investigate the pharmacokinetics of BP1.4979 following a 14-day dosing period with twice-daily administration of the sustained release formulation. The study is conducted in the context of **binge eating disorder** and is classified as a Phase 3 trial.

The trial is expected to commence recruitment on July 22, 2024, and conclude by October 31, 2024. Participants will undergo a series of study visits, beginning with an inclusion visit to screen for eligibility. This will be followed by multiple follow-up visits to monitor pharmacokinetic parameters and ensure participant safety. The end-of-study visit will mark the completion of the trial for each participant, during which final assessments will be conducted. The total duration of participant involvement will vary depending on the part of the study they are enrolled in, with Part II requiring a longer commitment due to the 14-day dosing regimen.

Participants may be subject to early termination from the study if they experience adverse events that compromise their safety, fail to comply with study procedures, or withdraw consent. The trial's design and procedures are structured to ensure rigorous data collection while maintaining participant safety and adherence to ethical standards.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this study, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. The absence of these details suggests that the trial documentation may be incomplete or that such information is not applicable to this particular study.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 3 study, indicating a focus on confirming the effectiveness of the intervention in a larger patient population. The trial is scheduled to commence recruitment on July 22, 2024, with an estimated completion date of October 31, 2024. Efficacy assessments will be conducted at predetermined intervals throughout the trial duration, utilizing standardized methods and tools appropriate for the condition under investigation. The specific parameters or endpoints for evaluating efficacy, such as symptom improvement scores or biomarker levels, are not detailed in the available data. The analysis of efficacy will be performed using scientifically validated techniques to ensure the reliability and validity of the results. The trial will adhere to rigorous protocols to maintain the integrity of the data collected and analyzed.